ARCHIVES

Pre-Emptive Treatment Helped Curtail Panitumumab Toxicity

This article is from The Cancer Letter archive.

Vol. 32 No. 1 | January 30, 2009

Download PDF Visit The Full Archive

Related Articles

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

January 13, 2006

Zubrod To Retire as Miami Director; Baker Succeeds Brennan As Director Of Detroit Center

January 29, 1988

In Brief: Baylor Campus to Build Joint Cancer Center

January 17, 2014

NCI Cooperative Group, Cancer Center Trials Listed

January 25, 2008

Broder On FDA: Don’t Blame Them For Doing Their Jobs (They Have To Work At Parklawn)

September 27, 1991

Pharmacia Says SU5416 Doesn’t Benefit Colorectal Cancer Patients, Closes Trial.

March 1, 2002